Kineta Inc's Customers Performance

Name: Kineta Inc Customers by Division and Industry - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use

KANT

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.


KANT's Source of Revenues		During the corresponding time, Kineta Inc While revenue at the Kineta Inc 's corporate clients • List of KANT Customers

for the same period Kineta Inc

• List of KANT Customers

Kineta Inc's Business Units

Select the Relationship:

Customers ▼

Select the Category:

Comparison ▼

Customers ▼

Basic Report▼

Kineta Inc's Comment on Sales, Marketing and Customers

News about Kineta Inc Contracts

Advancing Cancer Therapy Kineta Completes Enrollment in Phase 1 Clinical Study for Advanced Solid Tumors

In a significant milestone for cancer research and treatment, Kineta Inc. has announced the completion of patient enrollment in the monotherapy arm of its VISTA-101 Phase 1 clinical study, aimed at evaluating its investigational treatment for patients with advanced solid tumors. This study represents an important step in the ongoing search for innovative cancer therapies, particularly in indications where conventional treatments have limited efficacy. Study OverviewThe VISTA-101 clinical trial is designed to assess the safety, tolerability, and preliminary efficacy of Kineta’s novel investigational drug. By focusing on advanced solid tumors, which often present therapeutic challenges due to localized and s...

Kineta Expands Strategic Partnership with TuHURA Biosciences for KVA12123 Development

In a significant development for its ongoing pipeline of innovative therapeutic solutions, Kineta, Inc. has announced the extension of its exclusivity and right of first offer agreement with TuHURA Biosciences concerning the promising KVA12123, a VISTA blocking antibody currently in Phase 1 clinical trials. This announcement reaffirms Kineta s commitment to advancing its research and development initiatives in the field of immunotherapy and highlights the strategic alliance formed with TuHURA.Under the terms of the amended agreement, TuHURA will continue to hold exclusivity rights pertaining to the commercialisation of KVA12123, thereby allowing Kineta to maintain a focused approach to its clinical developme...

KANT's Stock Performance relative to it's Customers

KANT's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)

COMPANY NAME	MARKET CAP	REVENUES	INCOME	EMPLOYEES
Kineta Inc	4.34	0.00	-8.46	4
SUBTOTAL	0.00	0.00	0.00	-

Sources: Kineta Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Kineta Inc’s corporate clients.
For your research, we’ve provided 9 tables on Kineta Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.